BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 28494531)

  • 21. Screening for Colorectal Cancer Is Associated With Lower Disease Stage: A Population-Based Study.
    Kubisch CH; Crispin A; Mansmann U; Göke B; Kolligs FT
    Clin Gastroenterol Hepatol; 2016 Nov; 14(11):1612-1618.e3. PubMed ID: 27085763
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trends in colonoscopy and fecal occult blood test use after the introduction of dual screening offers in Germany: Results from a large population-based study, 2003-2016.
    Chen C; Stock C; Jansen L; Chang-Claude J; Hoffmeister M; Brenner H
    Prev Med; 2019 Jun; 123():333-340. PubMed ID: 30946858
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of lower gastrointestinal endoscopy and fecal occult blood test in the 2007 Swiss Health Interview Survey respondents aged 50 years and older.
    Spaeth A; Zwahlen M
    Endoscopy; 2013 Jul; 45(7):560-6. PubMed ID: 23780844
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Survival of patients with symptom- and screening-detected colorectal cancer.
    Brenner H; Jansen L; Ulrich A; Chang-Claude J; Hoffmeister M
    Oncotarget; 2016 Jul; 7(28):44695-44704. PubMed ID: 27213584
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer.
    Dinh T; Ladabaum U; Alperin P; Caldwell C; Smith R; Levin TR
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1158-66. PubMed ID: 23542330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Virtual colonoscopy, optical colonoscopy, or fecal occult blood testing for colorectal cancer screening: results of a pilot randomized controlled trial.
    You JJ; Liu Y; Kirby J; Vora P; Moayyedi P
    Trials; 2015 Jul; 16():296. PubMed ID: 26156248
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Contribution of patient, physician, and environmental factors to demographic and health variation in colonoscopy follow-up for abnormal colorectal cancer screening test results.
    Partin MR; Gravely AA; Burgess JF; Haggstrom DA; Lillie SE; Nelson DB; Nugent SM; Shaukat A; Sultan S; Walter LC; Burgess DJ
    Cancer; 2017 Sep; 123(18):3502-3512. PubMed ID: 28493543
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Colorectal cancer screening: comparison of transferrin and immuno fecal occult blood test.
    Chen JG; Cai J; Wu HL; Xu H; Zhang YX; Chen C; Wang Q; Xu J; Yuan XL
    World J Gastroenterol; 2012 Jun; 18(21):2682-8. PubMed ID: 22690078
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Self-perceived Mental Health Status and Uptake of Fecal Occult Blood Test for Colorectal Cancer Screening in Canada: A Cross-Sectional Study.
    Hategekimana C; Karamouzian M
    Int J Health Policy Manag; 2016 Feb; 5(6):365-71. PubMed ID: 27285514
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acceptance on colorectal cancer screening upper age limit in South Korea.
    Luu XQ; Lee K; Lee YY; Suh M; Kim Y; Choi KS
    World J Gastroenterol; 2020 Jul; 26(27):3963-3974. PubMed ID: 32774070
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increasing uptake of colorectal cancer screening in Korea: a population-based study.
    Choi KS; Jun JK; Lee HY; Hahm MI; Oh JH; Park EC
    BMC Public Health; 2010 May; 10():265. PubMed ID: 20492654
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lower risk of advanced neoplasia among patients with a previous negative result from a fecal test for colorectal cancer.
    Denters MJ; Deutekom M; Bossuyt PM; Stroobants AK; Fockens P; Dekker E
    Gastroenterology; 2012 Mar; 142(3):497-504. PubMed ID: 22108194
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Faecal occult blood testing for colorectal cancer screening: the past or the future.
    Benton SC; Seaman HE; Halloran SP
    Curr Gastroenterol Rep; 2015 Feb; 17(2):428. PubMed ID: 25673567
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term risk of colorectal cancer after negative colonoscopy in a Danish gFOBT screening cohort.
    Bjerrum A; Andersen O; Fischer A; Lindebjerg J; Lynge E
    Int J Cancer; 2017 Aug; 141(3):503-511. PubMed ID: 28463410
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The public prefers fecal occult blood test over colonoscopy for colorectal cancer screening.
    Almog R; Ezra G; Lavi I; Rennert G; Hagoel L
    Eur J Cancer Prev; 2008 Oct; 17(5):430-7. PubMed ID: 18714185
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Koreans’ Awareness and Preventive Behaviors Regarding Colorectal Cancer Screening.
    Lee SY
    Asian Pac J Cancer Prev; 2018 Sep; 19(9):2657-2664. PubMed ID: 30256565
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
    van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
    Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors associated with adherence to fecal occult blood testing for colorectal cancer screening among adults in the Republic of Korea.
    Bae N; Park S; Lim S
    Eur J Oncol Nurs; 2014 Feb; 18(1):72-7. PubMed ID: 24183583
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Colonoscopy vs. Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer (CONFIRM): Rationale for Study Design.
    Dominitz JA; Robertson DJ; Ahnen DJ; Allison JE; Antonelli M; Boardman KD; Ciarleglio M; Del Curto BJ; Huang GD; Imperiale TF; Larson MF; Lieberman D; O'Connor T; O'Leary TJ; Peduzzi P; Provenzale D; Shaukat A; Sultan S; Voorhees A; Wallace R; Guarino PD
    Am J Gastroenterol; 2017 Nov; 112(11):1736-1746. PubMed ID: 29016565
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness simulation and analysis of colorectal cancer screening in Hong Kong Chinese population: comparison amongst colonoscopy, guaiac and immunologic fecal occult blood testing.
    Wong CK; Lam CL; Wan YF; Fong DY
    BMC Cancer; 2015 Oct; 15():705. PubMed ID: 26471036
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.